Protalix BioTherapeutics, Inc. (FRA:PBDA)

Market Cap	143.12M
Revenue (ttm)	52.71M
Net Income (ttm)	4.60M
Shares Out	n/a
EPS (ttm)	0.06
PE Ratio	31.13
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	163
Open	1.730
Previous Close	1.700
Day's Range	1.720 - 1.840
52-Week Range	1.140 - 2.700
Beta	n/a
RSI	69.60
Earnings Date	Mar 17, 2026

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell e...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Dror Bashan
• Employees: 213
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PBDA

Financial Performance

In 2024, Protalix BioTherapeutics's revenue was $53.40 million, a decrease of -18.47% compared to the previous year's $65.49 million. Earnings were $2.93 million, a decrease of -64.73%.

Financial numbers in USD